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Nitric oxide (NO), which is derived from endothelial
NO synthase (eNOS), provides crucial signals for an-
giogenesis in the tumor microenvironment. Tetrahy-
drobiopterin (BH4) is an absolute requirement for
eNOS activity. In this study, we investigated whether
this activation is both maintained by a wild-type Ras/
phosphatidylinositol 3-kinase (PI3K)/Akt-positive
feedback loop in endothelial cells and affects tumor
angiogenesis. We found that supplementation of BH4
(via the pterin salvage pathway with Sep) increased
Akt/eNOS phosphorylation in both human eNOS-trans-
fected COS-7 cells and endothelial cells concomitant
with increases in NO production, cell proliferation, mi-
gration, and tube formation. This augmentation was
abrogated by a PI3K inhibitor. Sepiapterin (Sep) also
increased GTP-bound wild-type Ras and PI3K/Akt/
eNOS activation, which was prevented by the eNOS
inhibitor, N-Nitro-L-arginine methyl ester (L-NAME).
Furthermore, expression of GTP cyclohydrolase I
(the rate-limiting enzyme in de novo BH4 synthesis)
under doxycycline control potentiated in vivo tumor-
igenesis, tumor cell proliferation, as well as angio-
genesis. Conversely , both switching off GTP cyclo-
hydrolase I expression as well as inhibiting its
enzymatic activity significantly decreased eNOS ex-
pression and tumor vascularization. This study dem-
onstrates an important role for BH4 synthesis in
angiogenesis by the activation of eNOS for NO pro-
duction, which is maintained by a PI3K/Akt-positive
feedback loop through effects on wild-type Ras in
endothelial cells. Our findings suggest that BH4 syn-
thesis may be a rational target for antiangiogenesis
therapy for tumors. (Am J Pathol 2010, 177:2671–2680;
DOI: 10.2353/ajpath.2010.100025)
Growth of new blood vessels from pre-existing ones,
ensuring oxygen and nutrient supplies, is a crucial step in
tumor cell proliferation, growth, and metastasis. This
pathological angiogenesis is maintained by overpro-
duction of proangiogenic factors, which act via a vari-
ety of signaling pathways in tumor stroma.1 Recent
evidence suggests that nitric oxide (NO) provides cru-
cial signals for angiogenesis in the tumor microenvi-
ronment, where moderate levels of NO are proangio-
genic,2,3 chiefly increasing DNA synthesis, cell
proliferation and migration of endothelial cells to pro-
mote tumor angiogenesis.4
NO is a gaseous free radical, resulting from the con-
version of L-arginine to citrulline by three distinct forms of
NO synthase (NOS): endothelial NOS (eNOS), inducible
NOS, and neuronal NOS in different cell types and tis-
sues.5 eNOS is the principal isoform in tumor vascular
endothelial cells. Under pathological conditions, eNOS-
derived NO is the dominant stimulus to angiogenesis in
B16 melanomas.6 Inhibition of basal eNOS by caveolin-1,
a protein that sequesters eNOS in caveolae, attenuates
NO-dependent blood flow in tumors and delays their
growth as xenografts.7 Similarly, tumor growth is
enhanced in caveolin-1-deficient mice because of
increased microvascular permeability and angiogene-
sis.8 Inhibiting eNOS with L-arginine analogs (N-Nitro-
L-arginine methyl ester [L-NAME], NG-Methyl-L-argi-
nine [L-NMMA] and N-Nitro-L-arginine [L-NNA])
decreases both tumor blood flow and microvascular
permeability in breast cancer xenografts.4 Moreover, a
Phase I clinical trial has confirmed that L-NNA mark-
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edly reduces blood flow in tumors.9 This suggests that
eNOS-derived NO signaling is one of the key factors in
maintaining blood flow and inducing vascular hyper-
permeability for tumor progression.
eNOS activation for NO production can be induced by
the proangiogenic vascular endothelial growth factor, un-
dergoing complex phosphorylation modulation in endo-
thelial cells.10 In response to vascular endothelial growth
factor stimulation, phosphatidylinositol 3-kinase (PI3K)
class 1A, comprising two heterodimers of regulatory
(p85) and catalytic (p110) subunits, is recruited to the
plasma membrane where Akt is phosphorylated. The
activated Akt directly phosphorylates eNOS, leading to
the transiently increased NO production.11 This regula-
tory free radical participates in signaling processes, fos-
tering S-nitrosylation of a single cysteine residue (Cys118)
in wild-type Ras. The group of these small GTPases
converts the inactive GDP-bound Ras to the active GTP-
bound that in turn, up-regulates PI3K/Akt and eNOS to
maintain NO production. Although the formation of this
positive feedback loop plays a crucial role in promoting
tumor progression and T lymphocyte activation,12,13 its
role in regulating endothelial cells for angiogenesis is still
not explored.
eNOS redox activity requires tetrahydrobiopterin (BH4)
as a cofactor for NO production.14 When BH4 levels are
inadequate, eNOS preferentially produces superoxide
over NO15,16 and contributes to vascular oxidative stress
and angiogenesis regulation.17–19 BH4 is synthesized via
either the de novo pathway—GTP cyclohydrolase I (GCH;
EC 3.5.4.16) is the rate-limiting enzyme, converting GTP
to dihydroneopterin triphosphate before final generation
of BH4 by sepiapterin (Sep) reductase; or the pterin
salvage pathway—sepipaterin is a substrate.20 Essen-
tially BH4 synthesis has been directly associated with
activation of Akt and eNOS phosphorylation for NO pro-
duction.21,22 However, the precise mechanism by which
BH4 up-regulates phosphorylation of Akt and eNOS, and
affects angiogenesis is not known.
Tumor progression is strongly influenced by environ-
mental conditions and extracellular factors. GTP cyclohy-
drolase (GTPCH) gene expression is one of several dis-
tinct genes that are significantly up-regulated in the
stromal fibroblasts in colon cancer-associated liver me-
tastases.23 GTPCH activity favors tumor growth and is
clearly increased in patients with malignant tumors,20,24
correlating strongly with recurrence of many cancers,
particularly hematological and gynecological neoplasias,
and lung, prostate, hepatocellular and gastrointestinal
carcinoma.24–28 However, the role of GTPCH expression
in tumor stromal fibroblasts, especially in regulating an-
giogenesis, remains to be elucidated.
The purposes of this study, therefore, were to deter-
mine the proangiogenic role of BH4 synthesis and its
association with activation of eNOS and the wild-type
Ras/PI3K/Akt pathway in endothelial cells in vitro and to
evaluate the effects of GTPCH expression and BH4
synthesis in tumor stromal fibroblasts on angiogenesis
in vivo.
Materials and Methods
Reagents
Sepiapterin (Sep) was purchased from Schircks Laborato-
ries, and Ly294002 (LY) were obtained from Cell Signaling
Technology (Beverly, MA), and dissolved in dimethyl sul-
foxide (DMSO). 2,4-diamino-6-hydroxypyrimidine (DAHP)
was purchased from Alexis Biochemicals (San Diego, CA)
and dissolved in PBS.
Cell Culture
COS-7 and NIH3T3 Tet-off cells were grown in DMEM with
10% fetal bovine serum (FBS) in our laboratory, and primary
human umbilical vein endothelial cells (HUVEC) were pur-
chased from Lonza and grown in Endothelial Cell Growth
Medium-2 (EGM-2) medium with bullet kit at 37°C in 5%
CO2. HUVEC were used at passages 4 to 10. Before experi-
ments, the cells were deprived of FBS for 3 to 4 hours for
addition of reagents. All samples were determined in triplicate.
Transfection
Fifty percent of confluent monolayers of COS-7 cells that
are NOS deficient11 were transfected with the human
eNOS plasmid DNA (provided by Prof. S. Dimmeler of
University of Frankfurt, Frankfurt am, Germany) with Fu-
gene 6 reagent (Roche Diagnostics).
Western Blotting
Western blot analysis was performed as described pre-
viously.15 Briefly, cells were lysed in radioimmunoprecipi-
tation assay buffer (50 mmol/L Tris-HCl (pH 8) containing
0.2% Nonidet P-40, 180 mmol/L NaCl, 0.5 mmol/L EDTA,
100 mmol/L phenylmethylsulforyl fluoride, and 1 M di-
thiothreitol) containing phosphatase inhibitor (Roche
Diagnostics). Equal amounts of cellular proteins were
resolved by 12% SDS-PAGE and transferred to polyvi-
nylidene difluoride membranes. Immunoblotting was
performed using rabbit monoclonal antibodies (Cell Sig-
naling Technology) to phosphor (p)-eNOS (Ser1177) (1/
1000), eNOS (1/2500), p-Akt (Ser473) (1/1000), Akt (1/2500),
p-glycogen synthase kinase-3 beta (GSK3; 1/1000), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1/
2500). Immunodetection was accomplished using the
same donkey anti-rabbit secondary antibody (1/5000)
(Promega, Madison, WI). Bands were visualized using
chemiluminescence, and quantified using ImageJ soft-
ware. For detecting active Ras (a GTP-bound state), we
measured its ability to bind glutathione S-transferase fu-
sion protein linked to the Raf fragment that contains the
Ras-GTP binding domain GST-Raf-RBD. Lysates were
cleared by centrifugation and incubated for 1 hour at 4°C
with GST-Raf-RBD coupled to glutathione agarose beads
and washed four times with lysis buffer. The beads con-
taining GTP-bound Ras proteins were detected by West-
ern blotting with pan-Ras antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA).
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Measurement of NO Production
NO production in HUVEC was assayed using commercial
NO detection kit (Bachem) as described previously.29
The cells (1 105 cells/well) were grown in 96-well plates
and stained with diaminofluoresceine-diacetate (2DA), a
fluorescent probe, for NO at 37°C for 30 minutes, and
scanned on a fluorescence plate reader.
Determination of biopterins in cell and tissue lysates
was carried out as described previously.15 Briefly, cell
pellets or tissue frozen sections were lysed in cold extract
buffer (50 mmol/L Tris-HCl (pH 7.4), 1 mmol/L dithiothre-
itol, 1 mmol/L EDTA). Protein concentration was mea-
sured using the Bio-Rad protein assay. Proteins were
removed by adding 10 l of a 1:1 mixture of 1.5 M HClO4
and 2 M H3PO4 to 90 l of extracts, followed by centrif-
ugation. To determine total biopterins (BH4, BH2, and
biopterin) by acid oxidation 10 l of 1% iodine in 2%
potassium iodide (KI) solution was added to 90 l pro-
tein-free supernatant. To determine BH2 and biopterin by
alkaline oxidation, we added 10 l of 1 M NaOH to 80 l
of extract and then 10 l of iodine/potassium iodide (KI)
solution. Samples were incubated at room temperature
for 1 hour in the dark. Alkaline-oxidation samples were
then acidified with 20 l of 1 M H3PO4. Iodine was re-
duced by adding 5 l of fresh ascorbic acid (20 mg/ml).
Next, high-performance liquid chromatography was per-
formed using a Spherisorb ODS-1 column (Waters, Elstree,
UK) with a 10% methanol/90% water mobile-phase run at
0.4 ml/min. Fluorescence detection (350 nm excitation, 450
nm emission) was measured on an RF-10AXL detector (Shi-
madzu, Kyoto, Japan). BH4 concentrations, expressed as
picomoles per milligram protein, were calculated by sub-
tracting BH2  biopterin from total biopterins.
Cell Proliferation
HUVEC were plated at 5 104 cells/well in 1% of gelatin-
coated 12-well plates and cultured in Endothelial Cell
Growth Medium-2 (EGM-2) with 10% FBS without supple-
menting growth factors. Overnight after growth, cells
were incubated in FBS-free medium with Sep (10 mol/
L)  LY (10 mol/L) or the control (DMSO) for another 24
hours and counted with a Coulter counter (Beckman
Coulter, Fullerton, CA).
Cell Migration
HUVEC were plated at 5  105 cells/well and cultured in
Endothelial Cell Growth Medium-2 (EGM-2) with 2% FBS
and grown in growth factor-reduced Matrigel-precoated
cell culture insert (8 m pore size; Nunc, Naperville, IL).
Cells that migrated overnight through the pores to the
lower membrane were stained with Reastain Diff-Quick kit
(Reagena), and five random fields were counted.
Tubulogenesis
Ninety-six-well culture plates were coated with 50 l/well
of growth factor-reduced Matrigel (BD Biosciences, San
Jose, CA). HUVEC (1 105/well) were incubated with 2%
FBS for 24 hours, washed with PBS, and stained with 8
g/ml calcein-AM (Cambridge Bioscience, Cambridge,
UK). Numbers of loops were counted in images taken at
20 magnification.
Generation of Tetracycline-Regulated Human
GTPCH Expression in Murine Fibroblast Cells
An N-terminal HA epitope-tagged human GTPCH1 gene
was cloned into pTet-off plasmid that contains tetracy-
cline responsive element under cytomegalovirus pro-
moter control. We transfected this plasmid DNA into
NIH3T3 Tet-off cells that stably express tetracycline-con-
trolled transactivator.30 In the presence of doxycycline
(Dox), the tetracycline-controlled transactivator is blocked
and incapable of binding to tetracycline responsive ele-
ment, and therefore, activation of GTPCH1 gene is pre-
vented. After three rounds of hygromycin selection, cells
expressing HA-tagged human GTPCH (HA-GTPCH) and
responding to various doses of Dox inhibition were es-
tablished from expansion and termed “GCHtet-off,”
whereas control cells with empty vector transfection
alone was termed “Tet-off-EV.”
Fibroblast Implantation
GCHtet-off or Tet-off-EV in 100 l of 1  107 cell suspen-
sions with an equal volume of Matrigel (BD Biosciences)
were injected subcutaneously into flanks of 6- to 8-week-
old female BALB/c SCID mice (Harlan Sprague Dawley,
Indianapolis, IN) (n  5). Growth tumors were measured
two to three times per week using calipers, and volumes
were calculated as (length  width  height)/0.52. When
tumors reached the maximum size (1.44 cm2 surface
area) permitted by the Home Office license, the mouse
was sacrificed, and the tumor was excised. When
needed, Dox in the drinking water (2 g/L) with 5% of
sucrose or DAHP (an inhibitor of GTPCH for de novo BH4
synthesis) i.p. injection (300 mg/kg/day) was given for 7
days starting from day 25 when tumor volumes reached
100 mm3. All mouse studies were conducted in accor-
dance with protocols approved by the UK Home Office.
Immunohistochemistry
Paraffin-embedded tissue blocks from formalin-fixed tu-
mor samples were sectioned, dewaxed, and rehydrated
following standard protocols. Sections were stained for
Ki-67, a marker of cell proliferation, with rat anti-mouse
mindbomb homolog 1 (MIB-1) primary antibody (1/100)
and rabbit anti-rat horseradish peroxidase antibody (1/
200) (DakoCytomation, Glostrup, Denmark), and the pos-
itive cells counted in five randomly chosen fields. For
CD34, a marker of angiogenesis, we used rat anti-mouse
CD34 primary antibody (Serotec, Oxford, UK) and rabbit
anti-rat horseradish peroxidase antibody (DakoCytoma-
tion) and quantified microvessel densities by the
Chalkley method by defining three hotspot fields of
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vessels per section and five sections per tumor as
published previously.31 Expression of HA-GTPCH in
tumor was stained with rat anti-HA high affinity primary
antibody (Roche Diagnostics) and rabbit anti-rat
horseradish peroxidase antibody (DakoCytomation).
Statistics
Results are expressed as mean  SEM Statistical signif-
icance of differences between means was assessed us-
ing analysis of variance (ANOVA), followed by Student’s
unpaired two-tailed t-test and Bonferroni correction. A P
value of 0.05 was considered significant.
Results
Phosphorylation of eNOS and Akt by BH4
Synthesis via PI3K Pathway
To evaluate effects of BH4 synthesis on eNOS and Akt
phosphorylation, we initially used COS cells that were
transiently transfected with a human eNOS plasmid DNA.
The cells were incubated for 30 minutes with graded
doses of Sep in serum-free medium, and lysates were
analyzed by immunoblotting for eNOS and Akt proteins.
Sep clearly increased phosphorylation of eNOS (Ser1177)
and endogenous Akt (Ser473) in a dose-dependent man-
ner (Figure 1A).
BH4 Promotes HUVEC Proliferation, Migration,
and Tubule Formation Via PI3K Signaling
We then assessed the role of this pathway in regulating
biological functions of human endothelial cells. As shown
in Table 1, Sep greatly increased intracellular BH4 syn-
thesis and enhanced eNOS Ser1177 and Akt Ser473 in
HUVEC (Figure 1B), as in the COS cells. This augmenta-
tion required PI3K signaling, as it was prevented by LY
(Figure 1B), independently of BH4 synthesis (Table 1).
Moreover, Sep not only augmented NO production by
50%, but also significantly increased cell proliferation by
20%, cell migration and tubule formation by 3.5- and
2.5-fold, respectively (Figure 2, A–D). Since pretreatment
with LY inhibited each of these responses (Figure 2,
A–D), the induction of HUVEC proliferation, migration and
tubule formation by BH4 is apparently mediated by NO
production, dependent on the PI3K signaling.
Activation of the Wild-Type Ras Protein and
PI3K/Akt Pathway by BH4 Is Mediated by NO
Signaling in Endothelial Cells
To examine the mechanism of these responses further,
we incubated HUVEC with Sep  N-Nitro-L-arginine
methyl ester (L-NAME; 10 mol/L), which specifically
inhibits eNOS.15,32 We demonstrated that Sep increased
GTP-bound wild-type Ras (Figure 3A) and up-regulated
p85 (a PI3K regulatory subunit) by 40% (n  4) (Figure
3B). This augmentation correlated with increased levels
of both eNOS Ser1177 and Akt Ser473 (Figure 3C). In
contrast, N-Nitro-L-arginine methyl ester (L-NAME) pre-
treatment significantly decreased Sep-induced p85 ex-
pression and eNOS/Akt phosphorylation by at least 30%
(Figure 3, B and C). Our results suggest that increased
BH4 synthesis leading to the wild-type Ras activation and
Figure 1. Phosphorylation of eNOS and Akt by BH4 synthesis depends on
PI3K signaling in COS-7 cells and HUVEC. After overnight culture without
FBS, human eNOS-transfected COS-7 cell monolayers were incubated for 30
minutes with Sep at various doses (0, 2, 5, and 10 mol/L) or the control
(DMSO). Lysates were fractionated by SDS-PAGE and immunoblotted with
monoclonal antibody to p-eNOS (Ser1177), p-Akt (Ser473), and GAPDH (A).
HUVEC were cultured and pre-treated in Endothelial Cell Growth Medium-2
(EGM-2) without FBS. Lysates were analyzed as for COS-7 cells (B). Bands
intensity of p-eNOS and p-Akt were quantified on ImageJ software. Data are
shown as the mean  SEM (*P  0.05 vs. the control or SepLY, n  4)
(ANOVA).
Table 1. Effect of Sepiapterin on Cellular Biopterin
Production in Vascular Endothelial Cells
Condition
Total biopterin
(pmol/mg)
BH4
(pmol/mg)
HUVEC (DMSO) 2.2  0.13 0.7  0.07
Sep 45.8  18.8* 9.6  4.6*
LY 2.1  0.9 0.79  0.06
SepLY 52.1  22.0 10.1  4.3
HUVEC were incubated with Sep (10 mol/L) for 30 minutes with or
without pretreatment of LY (10 mol/L) for 1 hour or the vehicle control
(DMSO). Cell pellets were harvested, and biopterin levels were
determined by high-performance liquid chromatography using both
acid-base oxidation with fluorometric detection. Values shown are the
means  SEM of two triplicate determinations (n  6, *P  0.05 vs.
vehicle control, or LY determined by ANOVA).
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p85/Akt/eNOS up-regulation is mediated by NO signal-
ing in HUVEC.
Taken together, our data show that intracellular BH4
synthesis promotes PI3K-dependent phosphorylation of
Akt/eNOS, with a corresponding increase in endothelial
cell proliferation, migration and tubule formation. More-
over, the consequent elevation of NO is paralleled by
activating of endogenous wild-type Ras and PI3K signal-
ing as proposed in Figure 3D. Indeed, we suggest that
BH4 synthesis for NO production in endothelial cells is
maintained by a wild- type Ras/PI3K/Akt-positive feed-
back loop. This novel mechanism is potentially important
for angiogenesis induction.
Effects of GTPCH Expression and BH4
Synthesis in Tumor Stromal Fibroblasts on
Angiogenesis in Vivo
To determine the proangiogenic potential of GTPCH ex-
pression for BH4 synthesis in tumor stromal fibroblasts,
we implanted BALB/c SCID mice with GCHtet-off and
3T3tet-off-EV (as control), respectively (Figure 4A). We
demonstrated that GTPCH expression not only increased
fibroblast cell proliferation in tumor stroma (Figure 4B) but
also transformed them as they formed tumors (Figure
4A). They appeared by day 25 and grew rapidly to the
permitted maximum at day 37 (Figure 4B). By contrast,
3T3tet-off-EV tumor stroma rarely generated even small
nodules by day 43 (Figure 4A). By immunohistochemical
staining, the GCHtet-off showed fourfold greater Ki-67
(proliferation marker) and CD34 (angiogenesis marker)
counts than the 3T3tet-off-EV (Figure 4, B and C).
To demonstrate these effects specifically correlating
with GTPCH expression and BH4 synthesis in tumor stro-
mal fibroblasts, we then implanted BALB/c SCID mice
with GCHtet-off, where we could control GTPCH expres-
sion in vivo similarly to in vitro (Figure 5A). Mice with
tumors that had grown to 100 mm3 were then fed with
Dox in drinking water to switch off GTPCH expression or
injected with DAHP for 7 days to inhibit GTPCH enzy-
matic activity. The mice were sacrificed and tumors were
harvested. Both immunohistochemical staining and
Western blotting confirmed down-regulation of HA-
GTPCH expression by Dox (Figure 5, B and D). More-
over, we observed a concomitant 40% reduction in
CD34-positive microvessel counts with Dox and 60%
reduction with DAHP (Figure 5C). Western blotting anal-
ysis also showed 50 and 60% reduction of eNOS expres-
sion in Dox- or DAHP-treated tumors, respectively (Figure
5D), whereas iNOS was undetectable in both untreated
and treated tumors (data not shown). These effects also
correlated with a significant reduction of both total biop-
terin and BH4 in tumor stroma (Table 2). Our results
suggest that expressing GTPCH for BH4 synthesis in
tumor stromal fibroblasts has regulated the function of
eNOS so that it controls microvessel formation.
Interestingly, BH4 levels remained elevated in DAHP-
treated tumors and yet the microvessel density was lower
than in Dox-treated tumors where BH4 levels were low
(Table 2). To further understand the role of DAHP in tumor
Figure 2. Sep-induced NO production and cell proliferation, migration, and
tubule formation are dependent on PI3K signaling in HUVEC. A: Cells were
cultured and pretreated as for Figure 1. B–D: For proliferation (B), migration
(C), and tubule formation at  20 magnification (D), cells were incubated
with Sep (10 mol/L)  LY (10 mol/L) or the control (DMSO) for 24 hours.
Data are shown as the mean  SEM (*P  0.05 vs. the control or SepLY,
n  6) (ANOVA).
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angiogenesis, we incubated HUVEC with DAHP over-
night and analyzed the lysates by Western blotting. This
showed down-regulation of both eNOS phosphorylation
and expression in a dose dependent fashion (Figure 5E).
These results suggest that increased antiangiogenic po-
tency of DAHP is attributable to inhibiting BH4 synthesis
and additionally down-regulating eNOS expression.
Surprisingly, however, the late impairment in tumor
vessel formation with Dox or DAHP did not retard subse-
quent tumor growth or decrease Ki-67 expression (data
not shown). Possibly, earlier treatment of smaller tumors
might affect subsequent tumor growth, which was not
obvious here. Nevertheless, these results establish that
GTPCH expression and BH4 synthesis in the tumor stro-
mal fibroblasts promotes the microvessel vessel forma-
tion, strongly supporting the in vitro findings that in-
creased BH4 synthesis is a crucial factor for tumor
angiogenesis induction.
Discussion
The present study demonstrates that BH4 synthesis via
either the pterin salvage or the de novo pathway promotes
endothelial cell proliferation, migration, and tubule forma-
tion in cultures and induces angiogenesis in tumor xeno-
grafts. These effects correlated with increases in eNOS-
produced NO that depended, in turn, on the activation of
wild-type Ras and its downstream PI3K/Akt effectors in
vitro. Notably, genetically modified murine fibroblasts ex-
pressing GTPCH with concomitant increases in BH4 syn-
thesis showed a novel effect of neoplastic transformation
and induced tumor stromal fibroblast cell proliferation
and microvessel formation in vivo.
Previous studies have shown that increasing BH4 syn-
thesis can reverse the impaired proliferation found in
endothelial cells that are derived from diabetic rat aor-
tas.18 Conversely, indirectly decreasing BH4 levels by
depleting intracellular GTP, a substrate for de novo BH4
synthesis, reduces NO production and inhibits both en-
dothelial cell proliferation and tubule formation in vitro.19
However, a rigorous study of the molecular mechanisms
by which BH4 promotes angiogenesis in in vitro and in
vivo models remains unavailable. The present study
clearly showed that BH4 enhances NO production in
endothelial cells through the effects on wild-type Ras
activation and the downstream PI3K/Akt signaling re-
sponse. Furthermore, we established that GTPCH ex-
pression and BH4 synthesis in tumor stromal fibroblasts
promotes angiogenesis in vivo.
There is compelling evidence that cellular BH4 levels
govern eNOS catalytic activity.14,16,33 eNOS-derived NO
can be induced by a variety of stimuli (including vascular
endothelial growth factor), with extensive phosphoryla-
tion,10 dependent on the PI3K/Akt pathway.11,34 It was
observed that BH4 synthesis increases phosphorylation
of eNOS at Ser1177 in endothelial cells of the GCH-trans-
genic mouse model, with human GTPCH expressed spe-
cifically in endothelial cells, leading to NO-mediated va-
sodilatation.21 In contrast, because inhibition of de novo
BH4 synthesis by DAHP increases Thr497 phosphoryla-
tion rather than Ser1177, eNOS preferentially produces
superoxide rather than NO in mouse cardiac myocytes.35
Moreover, GTPCH knockdown impairs vascular endothe-
lial growth factor-initiated induction of eNOS activity, ac-
companied with eNOS dephosphorylation at Ser116; the
activity is restored by reconstituting BH4 in bovine endo-
Figure 3. Sep-activated wild-type Ras cascade
is mediated by NO in HUVEC. A: HUVEC were
cultured and pretreated  N-Nitro-L-arginine
methyl ester (L-NAME; 10 mol/L) or LY (10
mol/L) for one hour. Lysates were then incu-
bated with GST-Raf-RBD. After washing, the
pull-down proteins by agarose beads were frac-
tionated by SDS-PAGE and immunoblotted with
pan-Ras antibody to GTP-bound Ras and GST-
Raf-RBD. B and C: Lysates were also immuno-
blotted and analyzed for p85/p110, p-eNOS
(Ser1177), p-Akt (Ser473), and GAPDH. D: Sche-
matic diagram of proposing signaling.
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thelial cells.22 However, these observations only suggest
the links of BH4 synthesis in modulating eNOS. How
changes of BH4 synthesis modulate eNOS and Akt phos-
phorylation, and regulate angiogenesis, is still not clear.
The present study shows that the BH4 pterin salvage
synthetic pathway increases phosphorylation of both Akt
and eNOS in a dose-dependent manner in eNOS-trans-
fected COS cells. This effect depends on PI3K, as does
BH4 induced HUVEC proliferation, migration and tubule
formation. Our data then suggest that PI3K is one of
intermediate signaling pathways necessary for BH4-de-
pendent NO production in endothelial cells.
This raises intriguing questions about how Sep aug-
mented BH4 levels and the PI3K signaling interaction can
modify phosphorylation of Akt and eNOS. Although the
precise mechanisms by which Sep modifies Akt and
eNOS phosphorylation in HUVEC remains to be formally
proved, it is tempting to speculate that this occurs
through the intermediate production of NO and conse-
quently activation of wild-type Ras. Consistent with this
possibility, it has been reported in tumors that eNOS-
derived NO provides crucial feedback signaling to sub-
stantially activate PI3K signaling for Akt phosphorylation,
importantly mediated by wild-type Ras to favor onco-
genic Ras activity and hence tumorigenesis.4,12
The three Ras isoforms (H, K, and N-Ras) are small
GTPases that convert the inactive GDP-bound Ras to the
active GTP-bound form by recruiting Raf-1 or PI3K to the
plasma membrane to activate several key downstream
effectors, principally Akt.36–38 By phosphorylating eNOS,
Akt augments NO synthesis that in turn, is hypothesized
to promote S-nitrosylation of cysteines of Ras pro-
teins,12,13 as also occurs during activation of eNOS-
transfected T lymphocytes.13 That reciprocally drives the
PI3K/Akt pathway to maintain growth of tumors12 and
concomitant angiogenesis.39,40 Moreover, deletion of
p85, a regulatory subunit of PI3K, in mice has led to
partially decreased GTPCH expression and BH4 synthe-
sis activity, with subsequently attenuated NO production
from iNOS in macrophages.41 Our study extends these
findings, showing that BH4 synthesis via the pterin sal-
vage pathway increases GTP-bound Ras and up-regu-
lates the downstream effectors: p85 and Akt/eNOS, de-
pendent on NO signaling—supporting the notion that
BH4 synthesis for NO production is maintained by a
wild-type Ras/PI3K/Akt-positive feedback loop in endo-
thelial cells.
We also evaluated the effects of GTPCH expression
and BH4 synthesis in tumor stromal fibroblasts on angio-
genesis in vivo. We demonstrated that GTPCH expression
Figure 4. GTPCH overexpression and BH4 synthesis promote angiogenesis and tumor formation in mice. GCHtet-off cells (1 107) were injected s.c. into flanks
of 6- to 8-week-old female BALB/c SCID mice (n  5) and Tet-off-EV as control. Tumor volumes were monitored two to three times per week (A), when they
reached to maximum permitted volumes, mice were sacrificed, and tumors were sectioned and stained immunohistochemically for HA-GTPCH (red arrow-tumor
cells) (A), Ki-67 (B), and CD34 (C) at  20 magnification. Data are shown as the mean of five sections per animal  SEM (*P  0.05 vs. Tet-off-EV, n  5)
(ANOVA).
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greatly increased BH4 synthesis and dramatically in-
creased the stromal fibroblast cell proliferation and tumor
vascularization, also strikingly transformed murine fibro-
blasts. In contrast, both switching off GTPCH expression
and inhibiting its enzymatic activity selectively attenuated
tumor vessel formation, associated with decreased eNOS
expression and CD34 positive microvessels. These ef-
fects suggest a crucial role of GTPCH expression and
BH4 synthesis in tumor stroma, where they potentiate
tumor transformation and promote angiogenesis.
Intriguingly, we observed that in DAHP-treated tumors,
BH4 levels remain substantial, but the microvessel den-
sities are lower than in Dox-treated tumors. We hypothe-
sized that there may be additional inhibitory effects of
DAHP on tumor angiogenesis, independent on BH4 syn-
thesis; we found that DAHP down-regulates eNOS pro-
tein expression in a dose-dependent manner, corre-
sponding to decreased eNOS phosphorylation at
Ser1177. DAHP is conventionally recognized as a specific
competitive inhibitor of GTPCH as it has structural simi-
larity to GTP.42 It also acts indirectly on GTPCH by di-
rectly binding to a GTPCH feedback regulatory protein to
negatively inhibit GTPCH activity.43 A recent study has
shown further that DAHP can nonspecifically down-reg-
ulate other proteins in HUVEC, including cytokine-in-
duced expression of vascular cell adhesion molecule 1
and NF-B.44 Clearly, our understanding roles of DAHP in
antiangiogenesis in tumor remain preliminary. Additional
investigation is needed to study these issues.
Yet we observed that antiangiogenesis targeting GT-
PCH expression and BH4 synthesis had not affected
tumor stromal fibroblast cell proliferation or growth. This
does not agree with several previous reports, where ex-
ogenously added BH4 promoted the proliferation of
hemopoietic cells, mouse erythroleukemia and rat C6
glioma cells.45–47 That could reflect unexpected side
effects of high doses of Sep (100 mol/L) or nonspe-
cific growth factor stimulation. Additionally, our work is
on the stromal cells, rather than immortal fully trans-
formed human cancer cell lines. Our manipulation of
GTPCH might transform murine fibrolasts indepen-
dently of BH4 synthesis, a possible mechanism is cur-
rently under investigation.
In conclusion, NO is a free radical with complex sig-
naling actions in cancer.4 Emerging evidence suggests
NOS activity in tumor vasculature can be a novel target
for anticancer therapies.48 BH4 is absolutely required for
Figure 5. Both switch-off of GTPCH expression
and inhibition of BH4 synthesis decrease angio-
genesis in tumor stroma. HA-GTPCH expression
is highly regulated by Dox in GCHtet-off cell line
(A). GCHtet-off cells (1  107) were injected as
for Figure 4. When tumors reached to 100 mm3,
mice were fed with Dox in the drinking water or
i.p. injected with DAHP (300 mg/kg of body
weight) daily. After seven days, tumor sections
were stained for HA-GTPCH (B) and CD34 (C).
Data are shown as the mean of five sections per
animal  SEM (*P  0.05 vs. Dox or DAHP, n 
5) (ANOVA) (C). Tissue homogenates were an-
alyzed for eNOS, HA-GTPCH, and GAPDH (*P
0.05 vs. Dox or DAHP, n  5) (ANOVA) (D).
HUVEC were incubated with graded doses of
DAHP overnight, and lysates were assayed for
p-eNOS (Ser1177)/eNOS and GAPDH (represen-
tative of three experiments) (E).
Table 2. GTPCH Overexpression Results in de Novo BH4
Synthesis in Murine Fibroblast Implantation
Condition
Total biopterin
(pmol/mg)
BH4
(pmol/mg)
GCHtet-off 216.1  35.9* 198.5  32.5*
 DOX 23.7  3.2 12.2  3.0
 DAHP 93.4  20.3 81.0  19.1
GCHtet-off cells (1  107) were injected and treated with either Dox
or DAHP as for Figure 5. Tumor tissues were homogenized, and
biopterin levels were determined by high-performance liquid chromatography
using both acid-base oxidation with fluorometric detection. Values
shown are the means  SEM of animals (*P  0.05 vs. Dox or DAHP
determined by ANOVA).
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all NOS activity and is implicated in pathogenic actions of
eNOS.14 Increasing BH4 synthesis was known to in-
crease eNOS activity for NO production,49 thus enhanc-
ing tumor angiogenesis and growth. Here we show that
increased eNOS activation results from a positive feed-
back mechanism through the effects of NO signaling on
the wild-type Ras-PI3K/Akt pathway. Furthermore, aug-
mented BH4 synthesis in vivo by GTPCH expression in
tumor stromal fibroblasts strikingly potentiated tumor and
microvessel formation, indicating novel actions of GTPCH
on neoplastic transformation, tumor cell proliferation, and
angiogenesis.
Importantly, these in vitro and in vivo findings imply that
depleting BH4 levels in the tumor microenvironment, and
thus reducing NOS activity, could inhibit tumor angiogen-
esis at the same time increasing production of tumor-
cytotoxic superoxide. Hence we now provide proof-of-
principle that strategies targeting BH4 synthetic
pathways may be a rational approach to inhibiting tumor
angiogenesis and potentially tumor progression.
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